Claims for Patent: 11,033,551

Summary for Patent: 11,033,551

Title:	Methods of treating uterine fibroids
Abstract:	Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyr- idazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-- N'-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis. Further provided are methods of maintaining blood glucose profile, maintaining lipid profile, and/or maintaining bone mineral density in a pre-menopausal woman being treated for one or more conditions or symptoms of endometriosis, adenomyosis, uterine fibroids, or heavy menstrual bleeding; and methods of contraception and treating infertility.
Inventor(s):	Johnson; Brendan Mark (Chapel Hill, NC), Seely; Lynn (San Mateo, CA), Mudd, Jr.; Paul N. (Cary, NC), Wollowitz; Susan (Lafayette, CA), Hibberd; Mark (Hampshire, GB), Tanimoto; Masataka (Osaka, JP), Rajasekhar; Vijaykumar Reddy (Apple Valley, CA), Sukhatme; Mayukh Vasant (Mamaroneck, NY)
Assignee:	Myovant Sciences GmbH (Basel, CH) Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:	16/370,299
Patent Claims:	1. A method for treating uterine fibroids in a pre-menopausal woman in need thereof, the method comprising orally administering to the pre-menopausal woman, once-daily, a combination comprising about 40 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyr- idazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-- N'-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof; about 1.0 mg estradiol; and about 0.5 mg norethindrone acetate; wherein the pre-menopausal woman's ovarian estrogen production is suppressed, as demonstrated by prevention of ovulation; and wherein the pre-menopausal woman's bone mineral density during treatment is within .+-.3% of the pre-menopausal woman's bone mineral density prior to treatment. 2. The method of claim 1, wherein the pre-menopausal woman's bone mineral density during treatment is within .+-.2% of the pre-menopausal woman's bone mineral density prior to treatment. 3. The method of claim 1, wherein the pre-menopausal woman's daily serum estradiol concentration is between 20 pg/ml and 50 pg/ml between daily doses of the combination. 4. The method of claim 1, wherein one or both of the number and size of the uterine fibroids are reduced after beginning treatment compared to one or both of the number and size of the uterine fibroids prior to treatment. 5. The method of claim 1, wherein the pre-menopausal woman is a peri-menopausal woman. 6. A method for treating heavy menstrual bleeding associated with uterine fibroids in a pre-menopausal woman in need thereof, the method comprising orally administering to the pre-menopausal woman, once-daily, a combination comprising about 40 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyr- idazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-- N'-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof; about 1.0 mg estradiol; and about 0.5 mg norethindrone acetate; wherein the pre-menopausal woman's ovarian estrogen production is suppressed, as demonstrated by prevention of ovulation; and wherein the pre-menopausal woman's bone mineral density during treatment is within .+-.3% of the pre-menopausal woman's bone mineral density prior to treatment. 7. The method of claim 6, wherein the pre-menopausal woman's bone mineral density during treatment is within .+-.2% of the pre-menopausal woman's bone mineral density prior to treatment. 8. The method of claim 6, wherein the pre-menopausal woman's daily serum estradiol concentration is between 20 pg/ml and 50 pg/ml between daily doses of the combination. 9. The method of claim 6, wherein the pre-menopausal woman is a peri-menopausal woman. 10. The method of claim 6, wherein during treatment the pre-menopausal woman has: a menstrual blood loss volume of less than 80 mL per menstrual cycle; or a 50% reduction from baseline in menstrual blood loss volume, as compared to before beginning treatment; or a combination thereof. 11. The method of claim 6, wherein the pre-menopausal woman experiences a reduction in pain after beginning treatment compared to before treatment. 12. The method of claim 11, wherein the pain is pelvic pain. 13. The method of claim 12, wherein the pelvic pain is dysmenorrhea. 14. The method of claim 6, wherein the woman experiences an improvement in one or more of the following symptoms, which are selected from the group consisting of anemia, irregular periods, spotting, inflammation, pain, fatigue, urinary obstruction, urinary frequency, incontinence, constipation, anxiety, sleep disturbance, quality of life, activities of daily living, female sexual dysfunction, and depression. 15. The method of claim 6, wherein the pre-menopausal woman experiences amenorrhea after beginning treatment compared to prior to treatment. 16. The method of claim 6, wherein one or both of the number and size of the uterine fibroids are reduced after beginning treatment compared to one or both of the number and size of the uterine fibroids prior to treatment. 17. The method of claim 6, wherein uterine volume is reduced after beginning treatment compared to prior to treatment. 18. The method of claim 6, wherein during treatment the pre-menopausal woman's median serum follicle stimulating hormone (FSH) concentration is 2.1- to 4.1-fold reduced compared to the woman's median serum FSH concentration prior to treatment. 19. The method of claim 6, wherein the combination is administered for at least 24 consecutive weeks. 20. A method for treating heavy menstrual bleeding associated with uterine fibroids in a pre-menopausal woman in need thereof, the method comprising orally administering to the pre-menopausal woman, once-daily, a combination comprising about 40 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyr- idazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-- N'-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof; about 1.0 mg of estradiol or a corresponding amount of norethindrone acetate; and about 0.5 mg of norethindrone acetate; wherein the combination is administered for at least 4 consecutive weeks; wherein the pre-menopausal woman's ovarian estrogen production is suppressed, as demonstrated by prevention of ovulation; and wherein the pre-menopausal woman's bone mineral density during treatment is within .+-.3% of the pre-menopausal woman's bone mineral density prior to treatment. 21. The method of claim 1 wherein the combination is administered as a single dosage form. 22. The method of claim 1 wherein the combination comprises separate dosage forms that are co-administered. 23. The method of claim 6 wherein the combination is administered as a single dosage form. 24. The method of claim 6 wherein the combination comprises separate dosage forms that are co-administered. 25. The method of claim 20 wherein the combination is administered as a single dosage form. 26. The method of claim 20 wherein the combination comprises separate dosage forms that are co-administered.